ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2017 Pediatric Rheumatology Symposium

May 17-20, 2017. Houston, Texas.

View by Number View by Title View Sessions
View by Date

Thursday, May 18, 2017

5:30PM-7:00PM
Abstract Number: 76
Applying 2016 MAS Criteria to Systemic onset Juvenile Idiopathic Arthritis Patients with Diagnosis of Macrophage Activation Syndrome
Clinical and Therapeutic Poster Session
5:30PM-7:00PM
Abstract Number: 116
Arthritis as First Presenting Symptom of Inflammatory Bowel Disease: A Case Control Study
Clinical and Therapeutic Poster Session
5:30PM-7:00PM
Abstract Number: 87
Assessment of Endothelial Dysfunction and Atherogenic Risk Factors in Children with Juvenile Dermatomyositis
Clinical and Therapeutic Poster Session
5:30PM-7:00PM
Abstract Number: 106
Atypical manifestations and main misdiagnoses of Takayasu’s arteritis in childhood: a multicenter study of 71 patients
Clinical and Therapeutic Poster Session
5:30PM-7:00PM
Abstract Number: 131
Balancing JAK/STAT-signaling with tofacitinib may foster anti-inflammatory functions of human monocytes
Genetics and Pathogenesis Poster Session
5:30PM-7:00PM
Abstract Number: 65
Barriers at School for Children with Juvenile Idiopathic Arthritis (JIA) –A Patient Reported Outcome
Clinical and Therapeutic Poster Session
5:30PM-7:00PM
Abstract Number: 47
Baseline characteristics of the first 123 patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA comparative effectiveness study
Clinical and Therapeutic Poster Session
5:30PM-7:00PM
Abstract Number: 74
Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis
Clinical and Therapeutic Poster Session
5:30PM-7:00PM
Abstract Number: 97
Bortezomib is Efficacious in the Treatment of Refractory Neuropsychiatric SLE with Psychosis
Clinical and Therapeutic Poster Session
5:30PM-7:00PM
Abstract Number: 55
Celiac Disease in Children Diagnosed with Juvenile Idiopathic Arthritis
Clinical and Therapeutic Poster Session
5:30PM-7:00PM
Abstract Number: 129
Cell-bound Complement Activation Products Correlate with Disease Activity in Childhood-onset Systemic Lupus Erythematosus
Genetics and Pathogenesis Poster Session
5:30PM-7:00PM
Abstract Number: 126
Challenges in Transitioning Adolescents with Rheumatologic Diseases to Adult Care – The Brazilian Experience
Clinical and Therapeutic Poster Session
5:30PM-7:00PM
Abstract Number: 108
Characteristics and long-term outcome of children and adolescents with initial diagnosis of Behçet’s disease in a tertiary care center in Brazil
Clinical and Therapeutic Poster Session
5:30PM-7:00PM
Abstract Number: 85
Characteristics of anti-MDA5 autoantibody-associated Juvenile Dermatomyositis (JDM) in North America
Clinical and Therapeutic Poster Session
5:30PM-7:00PM
Abstract Number: 152
Characteristics of Patients With Juvenile Idiopathic Arthritis in a US Healthcare Claims Database
Quality, Health Services and Education Research Poster Session
  • «Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 10
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology